Tvardi Therapeutics, Inc. (TVRD)
Automate Your Wheel Strategy on TVRD
With Tiblio's Option Bot, you can configure your own wheel strategy including TVRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVRD
- Rev/Share 0.7979
- Book/Share 3.9928
- PB 1.1821
- Debt/Equity 0.0077
- CurrentRatio 4.0391
- ROIC -0.6967
- MktCap 44257014.0
- FreeCF/Share -3.83
- PFCF -1.4012
- PE -1.8629
- Debt/Assets 0.0058
- DivYield 0
- ROE 1.435
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TVRD | Raymond James | Outperform | Market Perform | -- | -- | Oct. 14, 2025 |
| Downgrade | TVRD | Barclays | Overweight | Equal Weight | -- | $5 | Oct. 14, 2025 |
| Initiation | TVRD | Barclays | -- | Overweight | -- | $61 | Oct. 13, 2025 |
| Downgrade | TVRD | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Oct. 13, 2025 |
| Downgrade | TVRD | Piper Sandler | Overweight | Neutral | $78 | $4 | Oct. 13, 2025 |
| Initiation | TVRD | Raymond James | -- | Outperform | -- | $62 | July 14, 2025 |
| Initiation | TVRD | Cantor Fitzgerald | -- | Overweight | -- | $52 | July 11, 2025 |
| Initiation | TVRD | Piper Sandler | -- | Overweight | -- | $78 | June 12, 2025 |
| Initiation | TVRD | Oppenheimer | -- | Outperform | -- | $65 | May 21, 2025 |
| Initiation | TVRD | BTIG Research | -- | Buy | -- | $55 | May 15, 2025 |
News
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Tvardi (TVRD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD).
Read More
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
Published: October 24, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting from allegations that Tvardi Therapeutics may have issued materially misleading business information to the investing public. So What: If you purchased Tvardi Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through.
Read More
Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD).
Read More
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Published: October 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD).
Read More
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Read More
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
Published: October 13, 2025 by: Benzinga
Sentiment: Negative
Tvardi Therapeutics Inc. (NASDAQ:TVRD) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.
Read More
About Tvardi Therapeutics, Inc. (TVRD)
- IPO Date 2025-04-16
- Website https://tvarditherapeutics.com​ BioSpace +4
- Industry Biotechnology
- CEO Imran Alibhai
- Employees 17